Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: BULGARIA - REVIEW
In per capita terms, the Bulgarian pharmaceutical market is one of the smallest in Central & Eastern Europe, similar in value to Romania. The market is predicted to increase at a moderate CAGR over the next few years. The growth rate has been affected by the economic crisis, with GDP contracting in 2009 and 2010. However, the economy is expected to recover in 2011. Health expenditure is expected to grow steadily over the next few years. In per capita terms, Bulgaria will have the second lowest level of spending in the region by 2016. Public health expenditure will continue to account for over half of total spending.
All Bulgarian pharmaceutical companies produce generics as they cannot afford to develop innovative drugs. Generics account for a large proportion of the pharmaceutical market in volume terms, with two thirds of this supplied by domestic manufacturers; Actavis (formerly Balkanpharma) and Sopharma are among the leading producers. With regard to patent laws, counterfeiting was rife in Communist times, leading to the presence of many copied versions of leading drugs on the Bulgarian pharmaceutical market. This practice has become less common, however, as Bulgaria has moved its regulations in line with international norms.
Multinationals are slowly expanding their presence in the market. Companies such as Novartis, Sanofi, GlaxoSmithKline and Pfizer hold small market shares, in volume terms. As industry procedures and standards become increasingly harmonised with Western practices, making the market more accessible, the presence of foreign drug companies is likely to rise. The Bulgarian pharmaceutical industry has undergone a process of considerable privatisation in recent years. The country's largest drug companies, Sopharma and the subsidiaries of Actavis, have all been partially privatised and account for the vast majority of domestic production. The presence of foreign companies such as Actavis has allowed some local companies to implement Good Manufacturing Practices at their facilities and strengthen their product portfolios.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: Bulgaria published by Espicom Business Intelligence in January 31, 2013. This report consists of 92 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
